ASCO 2014: Did diagnostics crash the biggest cancer drug party of the year?
This article was originally published in Scrip
Executive Summary
The American Society for Clinical Oncology (ASCO) may be one of the biggest meetings in the pharma industry's calendar but diagnostics firms are increasing their role in the action. Madeleine Armstrong looks at some of the highlights, as well as a flurry of deals that show companion diagnostics are no longer bit players on the cancer scene.